UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

European journal of cancer (1990), 2019-08, Vol.117, p.60-68

2019

Volltextzugriff (PDF)

Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type "window of opportunity"

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii183-viii184

2018

Volltextzugriff (PDF)

Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis

Annals of oncology, 2012-09, Vol.23 (9), p.2352-2356

2012

Volltextzugriff (PDF)

Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization

Annals of oncology, 2011-01, Vol.22 (1), p.86-92

2011

Volltextzugriff (PDF)

Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease

Current cancer drug targets, 2010-08, Vol.10 (5), p.496-508

2010

Volltextzugriff (PDF)

Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress

American journal of physiology. Heart and circulatory physiology, 2003-01, Vol.284 (1), p.H41-H48

2003

Volltextzugriff (PDF)

Detecting the disappearance of RAS-mutant clones in the plasma of patients with RAS-mutant mCRC to select patient candidates for anti-EGFR treatment and to monitor resistance to treatment

Annals of oncology, 2019-07, Vol.30, p.iv38-iv38

2019

Volltextzugriff (PDF)

2194 Isolation of circulating tumor cells with stem-like features in metastatic colorectal cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S398-S398

2015

Volltextzugriff (PDF)

EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer

Annals of oncology, 2019-04, Vol.30, p.ii7-ii7

2019

Volltextzugriff (PDF)

Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?

Journal of cancer research and clinical oncology, 2013-08, Vol.139 (8), p.1411-1416

2013

Volltextzugriff (PDF)

Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer

Annals of oncology, 2003-01, Vol.14 (1), p.85-90

2003

Volltextzugriff (PDF)

Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero

Annals of oncology, 2011-08, Vol.22 (8), p.1929-1930

2011

Volltextzugriff (PDF)

The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide

The American journal of clinical nutrition, 2000-11, Vol.72 (5), p.1150-1155

2000

Volltextzugriff (PDF)

CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients

European journal of surgical oncology, 2010-12, Vol.36 (12), p.1211-1214

2010

Volltextzugriff (PDF)

Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer

Journal of endocrinology, 2007-07, Vol.194 (1), p.55-61

2007

Volltextzugriff (PDF)

Circulating tumor cells in cancer therapy: are we off target?

Current cancer drug targets, 2010-08, Vol.10 (5), p.509-518

2010

Volltextzugriff (PDF)

Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy

Current cancer drug targets, 2008-08, Vol.8 (5), p.414-420

2008

Volltextzugriff (PDF)

1777P 13 genes panel validation to assess minimal residual disease through urinary tumor DNA in muscle-invasive bladder cancer patients

Annals of oncology, 2022-09, Vol.33, p.S1350

2022

Volltextzugriff (PDF)

549PSecond line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type "window of opportunity"

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

3MO Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors

Annals of oncology, 2021-10, Vol.32, p.S1345-S1346

2021

Volltextzugriff (PDF)

1252P Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2021-09, Vol.32, p.S983-S983

2021

Volltextzugriff (PDF)

Platelet activation and cytokine production during hypothermic cardiopulmonary bypass--a possible correlation?

Thrombosis and haemostasis, 1998-07, Vol.80 (1), p.58-64

1998

Volltextzugriff (PDF)

127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma

Annals of oncology, 2022-10, Vol.33, p.S1423-S1423

2022

Volltextzugriff (PDF)

ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC

Annals of oncology, 2017-09, Vol.28, p.v586-v586

2017

Volltextzugriff (PDF)

Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide

Arteriosclerosis, thrombosis, and vascular biology, 1999-10, Vol.19 (10), p.2542-2547

1999

Volltextzugriff (PDF)

1 – 25 von 333

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(263)
Mit Volltextzugriff
(234)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(217)
Life Sciences & Biomedicine
(203)
Humans
(187)
Biological And Medical Sciences
(122)
Male
(104)
Medical Sciences
(99)
Female
(91)
Middle Aged
(80)
Adult
(68)
Aged
(52)
Oncology
(43)
Neurosciences & Neurology
(39)
Pharmacology. Drug Treatments
(38)
Neurosciences
(33)
Cardiovascular System & Cardiology
(29)
Pharmacology & Pharmacy
(29)
Hematology
(26)
Fundamental And Applied Biological Sciences. Psychology
(25)
Social Sciences
(24)
Animals
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type "window of opportunity"

Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis

Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization

Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease

Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress

Detecting the disappearance of RAS-mutant clones in the plasma of patients with RAS-mutant mCRC to select patient candidates for anti-EGFR treatment and to monitor resistance to treatment

2194 Isolation of circulating tumor cells with stem-like features in metastatic colorectal cancer

EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer

Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?

Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer

Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero

The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide

CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients

Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer

Circulating tumor cells in cancer therapy: are we off target?

Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy

1777P 13 genes panel validation to assess minimal residual disease through urinary tumor DNA in muscle-invasive bladder cancer patients

549PSecond line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type "window of opportunity"

3MO Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors

1252P Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)

Platelet activation and cytokine production during hypothermic cardiopulmonary bypass--a possible correlation?

127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma

ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC

Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide

Suchergebnisse filtern